Papp Kim A, Puig Luis, Beecker Jennifer, Chandran Vinod, Claveau Joël, Cortés Javier, Dutz Jan, Hornick Noah I, Juergens Rosalyn A, Melosky Barbara, Patel Anisha B, Sauder Maxwell B, Sehdev Sandeep, Sibaud Vincent, Snow Stephanie L
Probity Medical Research Inc., Waterloo, Ontario, Canada.
Alliance Clinical Research, Waterloo, Ontario, Canada.
J Eur Acad Dermatol Venereol. 2025 Jul 21. doi: 10.1111/jdv.20809.
Immune checkpoint inhibitors (ICIs) are increasingly used to treat various cancers. Their use may result in immune-related adverse events, including psoriasis. When managing psoriasis, induced or exacerbated by an ICI, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis (saPs) and the potential impact on ICI efficacy. No direct, high-level evidence exists to address these concerns.
To address clinically relevant questions regarding the management of ICI-mediated psoriasis (ICI-Ps) with saPs.
We convened a multidisciplinary panel of 15 international specialists in dermatology, oncology, immunology, and rheumatology. A Delphi process defined clinical concerns related to the systemic treatment of ICI-Ps, focusing on the potential of saPs to impact ICI effectiveness. The saPs considered included biologics targeting tumour necrosis factor, interleukin (IL)-17, IL-12/23 and IL-23, traditional systemic therapies (cyclosporine, methotrexate), small molecules targeting phosphodiesterase-4 or tyrosine kinase 2, systemic retinoids (acitretin), and systemic corticosteroids. A systematic review of the literature was supplemented with evidence supporting an inference-based methodology to derive conclusions on the use of systemic therapies in patients with ICI-Ps. The specialist panel rated the strength of the conclusions using a probabilistic scale.
After reviewing the totality of direct and indirect evidence, we drafted inference-based conclusions and ascribed a level of support, focusing on the potential impact of saPs on ICI efficacy. This work provides a structured framework informing healthcare professional and patient discussions on the risks and benefits of using saPs in patients with cancer who experience ICI-Ps.
Although there is no direct evidence, we support the following conclusions: saPs may be used to treat ICI-Ps without an appreciable loss of ICI effectiveness. Generally, it is not necessary to interrupt ICI therapy. When available, non-steroid saPs are preferred over systemic corticosteroids for the treatment of psoriasis.
